- Effects of Quercetin on Cardiometabolic Outcomes — Recruiting • Non-phase study • Diabetes / Metabolic • NCT06230861.
- Quercetin supplement compared to placebo in randomized trial to test whether it improves heart disease and diabetes risk factors.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention. Conditions: Cardiometabolic Syndrome Interventions: Quercetin, Placebo Lead Sponsor: University of Central Lancashire Planned Enrollment: 40 participants